Economics Of Precision Medicine: Will It Lower Drug Costs?
This article was originally published in Scrip
While some have asserted tailoring treatments and cures to individuals will make therapies significantly more expensive, Francis Collins, director of the National Institutes of Health (NIH), said he thinks there's a "fair chance" precision medicine approaches will actually lead to a drop in research and development costs, thereby lowering the amounts patients pay for those products.
You may also be interested in...
Progress has been made in areas such as lung and breast cancer, but panelists at a recent conference noted there are many efficiencies yet to be realized in drug development and reimbursement.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.